ArticleScientific reports2026
Synthesis, characterisation and evaluation of polyethylene glycol-β-cyclodextrin-curcumin-zinc oxide nanoparticles for mosquitocidal, antibacterial and anticancer applications.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Curcumin-loaded PEGylated Magnetic Iron Oxide Nanoparticles: a Biogenic Platform for Targeted and Controlled Drug Release.Applied biochemistry and biotechnology · 2026Article
- Curcumin-loaded PEGylated Magnetic Iron Oxide Nanoparticles: a Biogenic Platform for Targeted and Controlled Drug Release.Applied biochemistry and biotechnology · 2026Article
- Article
- Photophysical characterization, biocompatibility and anticancer studies of green fabricated copper doped zirconium dioxide nanoparticles derived from Clitoria ternatea.Discover nano · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
To synthesise and characterise polyethylene glycol-β-cyclodextrin-curcumin-zinc oxide nanoparticles (PEG-Beta-Cur-ZnO NPs) and evaluate their stability, anti-mosquitocidal, antibacterial, and anticancer activities for potential biomedical and vector-control applications. Characterisation was performed using UV-Vis spectroscopy, Fourier Transform Infrared Spectroscopy (FTIR), X-ray Diffraction (XRD), and Transmission Electron Microscopy (TEM). Stability was assessed over time and pH ranges. Biological activity was evaluated through anti-malarial larval toxicity assays, adult mosquito longevity and fecundity studies, antibacterial assays against Escherichia coli and Staphylococcus aureus, and anticancer tests on HeLa cells measuring ROS generation, cell viability, DNA damage, and mitochondrial membrane potential. UV-Vis spectra confirmed successful functionalization with peak shifts to 423 nm. Stability studies showed time-limited dispersion (up to ~ 90 min) but improved stability under acidic conditions. FTIR revealed characteristic O-H, C=O, and Zn-O bands, confirming conjugation. XRD analysis indicated a preserved hexagonal wurtzite structure with high crystallinity. TEM imaging showed quasi-spherical morphology (76 nm). In larval assays, PEG-Beta-Cur-ZnO NPs achieved near-complete mortality at lower doses compared to free curcumin, while adult mosquitoes exhibited reduced lifespan and fecundity. Histopathology confirmed severe midgut damage in treated larvae. Antibacterial testing demonstrated superior inhibition zones and elevated ROS generation with PEG-Beta-Cur-ZnO NPs, indicating enhanced bacterial killing. In HeLa cells, the formulation induced significant ROS production, increased cell death, DNA fragmentation, and mitochondrial dysfunction compared to curcumin and ZnO NPs alone. PEG-Beta-Cur-ZnO NPs exhibit effective surface functionalization, pH-sensitive stability, and significantly enhanced larvicidal, antibacterial, and anticancer activities. These multifunctional nanoparticles show strong potential for eco-friendly vector control and biomedical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.